Status:
COMPLETED
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
Lead Sponsor:
Dartmouth-Hitchcock Medical Center
Collaborating Sponsors:
Sanofi
Hoffmann-La Roche
Conditions:
Esophageal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patie...
Detailed Description
This dose-ranging trial is designed to establish the phase II dose of capecitabine that can safely be given with docetaxel and radiation therapy for the treatment of patients with cancer of the esopha...
Eligibility Criteria
Inclusion
- Esophageal or gastroesophageal junction cancer that is locally advanced and surgically resectable (stage II or III disease).
- No prior therapy.
- Adequate organ function.
Exclusion
- Evidence of metastasis (celiac axis lymph nodes are allowed).
- Cervical esophageal tumors.
- Peripheral or auditory neuropathy grade \>= 2.
Key Trial Info
Start Date :
February 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00153881
Start Date
February 1 2000
End Date
September 1 2013
Last Update
November 13 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States, 03756